Literature DB >> 20345439

Patent foramen ovale among patients with mild chronic obstructive pulmonary disease and unexplained hypoxia.

Harun Kilic1, Mustafa M Balci, Murat N Aksoy, Esra Bilgin, Kevser G Gülsoy, Ekrem Yeter, Sadik Acikel, Ramazan Akdemir.   

Abstract

PURPOSE: To evaluate whether patent foramen ovale (PFO) is a contributing factor to hypoxia in patients with chronic obstructive pulmonary disease (COPD).
METHODS: Twenty-one patients over 40 years of age with mild COPD (Forced expiratory volume (FEV1)/Forced Vital Capacity (FVC): > 50%) who had hypoxia (PO(2) < 80 mmHg, SaO(2) < 95%) that could not be explained by COPD alone were included in this study. Arterial oxygen pressures (PO(2)) and arterial oxygen saturations (SaO(2)) were recorded from laboratory evaluations of arterial blood gases. Respiratory function tests were performed to analyze the degree of COPD. Standard and contrast echocardiography was used to calculate pulmonary artery pressure (PAP) levels and to determine patients with a PFO.
RESULTS: The mean age of the patients was 64 +/- 12 years. Four patients (19%) had a PFO. The mean PO(2), mean SaO(2), and mean PAP levels were 57.4 +/- 6.8 mmHg, 90 +/- 3.2%, and 33.8 +/- 5.4 mmHg, respectively, in patients without PFO. The mean PO(2), mean SaO(2), and mean PAP levels were 46.5 +/- 13.7 mmHg, 79.3 +/- 12.8%, and 42.5 +/- 6.5 mmHg, respectively, in patients with PFO. There were no statistically significant differences noted between the two groups in the PO(2) levels (P = 0.172) and SaO(2) levels (P = 0.065). A comparison of the PAP levels revealed a statistically significant difference between the two groups, with values that were more elevated in the PFO group than in the non-PFO group (P = 0.031).
CONCLUSION: This study demonstrated that PFO is not a contributing factor to deep hypoxia in COPD patients with lower PO(2) and SaO(2) levels; however, higher PAP levels were detected in patients with a PFO. Further studies involving a larger number of patients are needed to be conclusive.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20345439     DOI: 10.1111/j.1540-8175.2009.01105.x

Source DB:  PubMed          Journal:  Echocardiography        ISSN: 0742-2822            Impact factor:   1.724


  6 in total

1.  Significance of Patent Foramen Ovale in Patients with GOLD Stage II Chronic Obstructive Pulmonary Disease (COPD).

Authors:  Dario Martolini; Rebecca Tanner; Claire Davey; Mehul S Patel; Davide Elia; Helen Purcell; Paolo Palange; Nicholas S Hopkinson; Michael I Polkey
Journal:  Chronic Obstr Pulm Dis       Date:  2014-09-25

2.  Patent Foramen Ovale in COPD and Hypoxia: Innocent Bystander or Novel Therapeutic Target?

Authors:  Brett E Fenster; John D Carroll
Journal:  Chronic Obstr Pulm Dis       Date:  2014-09-25

3.  Unexplained hypoxemia in COPD with cardiac shunt.

Authors:  Rino Frizzelli; Corrado Lettieri; Simone Caiola; Linda Maulucci; Claudio Pinzi; Francesco Agostini; Annalisa Frizzelli
Journal:  Respir Med Case Rep       Date:  2022-05-05

4.  Exercise treadmill saline contrast echocardiography for the detection of patent foramen ovale in hypoxia.

Authors:  Brett E Fenster; Andrew M Freeman; Lori Silveira; J Kern Buckner; Douglas Curran-Everett; John D Carroll
Journal:  Int J Cardiovasc Imaging       Date:  2015-08-01       Impact factor: 2.357

Review 5.  Potential Role of Patent Foramen Ovale in Exacerbating Hypoxemia in Chronic Pulmonary Disease.

Authors:  Michael E Layoun; Jamil A Aboulhosn; Jonathan M Tobis
Journal:  Tex Heart Inst J       Date:  2017-06-01

6.  Patent foramen ovale is not associated with hypoxemia in severe chronic obstructive pulmonary disease and does not impair exercise performance.

Authors:  Zarrin F Shaikh; Julia L Kelly; Dinesh Shrikrishna; Manuel de Villa; Michael J Mullen; Nicholas S Hopkinson; Mary J Morrell; Michael I Polkey
Journal:  Am J Respir Crit Care Med       Date:  2014-03-01       Impact factor: 21.405

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.